Carteolol

From Self-sufficiency
Jump to: navigation, search
Carteolol
File:Carteolol skeletal.svg
Systematic (IUPAC) name
(RS)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
oral
Pharmacokinetic data
Bioavailability 85%
Metabolism Hepatic, active with 8-hydrocarteolol
Biological half-life 6–8 hours
Excretion Renal (50-70%)
Identifiers
CAS Number 51781-06-7
ATC code C07AA15 (WHO) S01ED05
PubChem CID 2583
DrugBank APRD00195
ChemSpider 2485
Chemical data
Formula C16H24N2O3
Molar mass 292.373 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Carteolol (Cartrol, Ocupress, Teoptic, Arteolol, Arteoptic, Calte, Cartéabak, Carteol, Cartéol, Cartrol, Elebloc, Endak, Glauteolol, Mikelan, Poenglaucol, Singlauc, ) is a non-selective beta blocker used to treat glaucoma.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

  • El-Kamel A, Al-Dosari H, Al-Jenoobi F (2006). "Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride". Drug Deliv. 13 (1): 55–9. doi:10.1080/10717540500309073. PMID 16401594. 
  • Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (2005). "Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro". Cornea. 24 (2): 213–20. doi:10.1097/01.ico.0000141232.41343.9d. PMID 15725891. 
  • Trinquand C, Romanet J, Nordmann J, Allaire C (2003). "[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]". J Fr Ophtalmol. 26 (2): 131–6. PMID 12660585. 


es:Carteolol

it:Carteololo nl:Carteolol pl:Karteolol